Biosensors in clinical practice: Focus on oncohematology

Sensors (Switzerland)

Volumn 13, Issue 5, 2013, Pages 6423-6447

  Fracchiolla, Nicola S ^a   Artuso, Silvia ^a   Cortelezzi, Agostino ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Biosensors; Clinical applications; Leukemia; Oncohematology

Indexed keywords

DISEASES; ENERGY TRANSFER;

ACUTE MYELOID LEUKEMIA; CHRONIC MYELOID LEUKEMIAS; CLINICAL APPLICATION; FLUORESCENCE RESONANCE; FUTURE PERSPECTIVES; HEMATOLOGICAL MALIGNANCIES; LEUKEMIA; ONCOHEMATOLOGY;

BIOSENSORS;

EID: 84878031324     PISSN: 14248220     EISSN: None     Source Type: Journal    
DOI: 10.3390/s130506423     Document Type: Review

References (96)

1. Fetz, V.; Knauer, S.K.; Bier, C.; von Kries, J.P.; Stauber, R.H. Translocation biosensors-cellular system integrators to dissect CRM1-dependent nuclear export by chemicogenomics. Sensors 2009, 9, 5423-5445.
2. Newman, J.D.; Setford, S.J. Enzymatic biosensors. Mol. Biotechnol. 2006, 32, 249-268.
3. Bohunicky, B.; Mousa, S.A. Biosensors: The new wave in cancer diagnosis. Nanotechnol. Sci. Appl. 2011, 4, 1-10.
4. Tothill, I.E.; Turner, A.P.F. Bionsensors. In Encyclopedia of Food Sciences and Nutrition; Caballero, B., Trugo, L., Finglas, P., Eds.; Academic Press: New York, NY, USA, 2003; pp. 489-499.
5. Morrison, D.W.G.; Dokmeci, M.R.; Demirci, U.; Khademhosseini, A. Clinical Applications of Micro- and Nanoscale Biosensors. In Biomedical Nanostructures; Gonsalves, K.E., Halberstadt, C.R., Laurencin, C.T., Nair, L.S., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2007; pp. 433-454.
6. Mehrvar, M.; Abdi, M. Recent developments, characteristics, and potential applications of electrochemical biosensors. Anal. Sci. 2004, 20, 1113-1126.
7. Tothill, I.E. Biosensors for cancer markers diagnosis. Semin. Cell Dev. Biol. 2009, 20, 55-62.
8. Monošík, R.; Streďanský, M.; Šturdík, E. Biosensors-classification, characterization and new trends. Acta Chim. Slovaca 2012, 5, 109-120.
9. Onen, O.; Ahmad, A.A.; Guldiken, R.; Gallant, N.D. Surface modification on acoustic wave biosensors for enhanced specificity. Sensors 2012, 12, 12317-12328.
10. Roh, S.; Chung, T.; Lee, B. Overview of the characteristics of micro- and nano-structured surface plasmon resonance sensors. Sensors 2011, 11, 1565-1588.
11. Pillet, F.; Sanchez, A.; Formosa, C.; Séverac, M.; Trévisiol, E.; Bouet, J.Y.; Anton Leberre, V. Dendrimer functionalization of gold surface improves the measurement of protein-DNA interactions by surface plasmon resonance imaging. Biosens. Bioelectron. 2013, 43, 148-154.
12. Zheng, R.; Cameron, B.D. Surface plasmon resonance: Recent progress toward the development of portable real-time blood diagnostics. Expert Rev. Mol. Diagn. 2012, 12, 5-7.
13. Van der Merwe, P.A. Surface Plasmon Resonance. In Protein-Ligand Interactions: Hydrodynamics and Calorimetry; Harding, S., Chowdhry, P.Z., Eds.; Oxford University Press: New York, NY, USA, 2001; pp. 137-170.
14. Kuo, Y.C.; Ho, J.H.; Yen, T.J.; Chen, H.F.; Lee, O.K. Development of a surface Plasmon resonance biosensor for real-time detection of osteogenic differentiation in live mesenchymal stem cells. PLoS One 2011, 6, e22382.
15. Chen, C.Y.; Chang, C.C.; Yu, C.; Lin, C.W. Clinical application of surface Plasmon resonance-based biosensors for fetal fibronectin detection. Sensors 2012, 12, 3879-3890.
16. Yuan, J.; Duan, R.; Yang, H.; Luo, X.; Xi, M. Detection of serum human epididymis secretory protein 4 in patients with ovarian cancer using a label-free biosensor based on localized surface plasmon resonance. Int. J. Nanomed. 2012, 7, 2921-2928.
17. Aoki, K.; Komatsu, N.; Hirata, E.; Kamioka, Y.; Matsuda, M. Stable expression of FRET biosensors: A new light in cancer research. Cancer Sci. 2012, 103, 614-619.
18. Day, R.N.; Davidson, M.W. Fluorescent proteins for FRET microscopy: Monitoring protein interactions in living cells. Bioessays 2012, 34, 341-350.
19. Zadran, S.; Standley, S.; Wong, K.; Otiniano, E.; Amighi, A.; Baudry, M. Fluorescence resonance energy transfer (FRET)-based biosensors: Visualizing cellular dynamics and bioenergetics. Appl. Microbiol. Biotechnol. 2012, 96, 895-902.
20. Kiyokawa, E.; Hara, S.; Nakamura, T.; Matsuda, M. Fluorescence (Förster) resonance energy transfer imaging of oncogene activity in living cells. Cancer Sci. 2006, 97, 8-15.
21. Waterhouse, B.R.; Gijsen, M.; Barber, P.R.; Tullis, I.D.; Vojnovic, B.; Kong, A. Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers. Oncotarget 2011, 2, 728-736.
22. Kim, K.; Barhoumi, R.; Burghardt, R.; Safe, S. Analysis of estrogen receptor alpha-Sp1 interactions in breast cancer cells by fluorescence resonance energy transfer. Mol. Endocrinol. 2005, 19, 843-854.
23. Xia, Z.; Rao, J. Biosensing and imaging based on bioluminescence resonance energy transfer. Curr. Opin. Biotechnol. 2009, 20, 37-44.
24. Prinz, A.; Diskar, M.; Herberg, F.W. Application of bioluminescence resonance energy transfer (BRET) for biomolecular interaction studies. Chembiochem 2006, 7, 1007-1012.
25. Prasher, D.C.; Eckenrode, V.K.; Ward, W.W.; Prendergast, F.G.; Cormier, M.J. Primary structure of the Aequorea victoria green-fluorescent protein. Gene 1992, 111, 229-233.
26. Saito, K.; Chang, Y.F.; Horikawa, K.; Hatsugai, N.; Higuchi, Y.; Hashida, M.; Yoshida, Y.; Matsuda, T.; Arai, Y.; Nagai, T. Luminescent proteins for high-speed single-cell and whole-body imaging. Nat. Commun. 2012, 3, 1262-1270.
27. Compan, V.; Baroja-Mazo, A.; Bragg, L.; Verkhratsky, A.; Perroy, J.; Pelegrin, P. A genetically encoded IL-1b bioluminescence resonance energy transfer sensor to monitor inflammasome activity. J. Immunol. 2012, 189, 2131-2137.
28. Balla, A.; Tóth, D.J.; Soltész-Katona, E.; Szakadáti, G.; Erdélyi, L.S.; Várnai, P.; Hunyady, L Mapping of the localization of type 1 angiotensin receptor in membrane microdomains using bioluminescence resonance energy transfer-based sensors. J. Biol. Chem. 2012, 287, 9090-9099.
29. Singh, A.; Poshtiban, S.; Evoy, S. Recent advances in bacteriophage based biosensors for food-borne pathogen detection. Sensors 2013, 13, 1763-1786.
30. Frascione, N.; Pinto, V.; Daniel, B. Development of a biosensor for human blood: New routes to body fluid identification. Anal. Bioanal. Chem. 2012, 404, 23-28.
31. Caygill, J.S.; Davis, F.; Higson, S.P. Current trends in explosive detection techniques. Talanta 2012, 88, 14-29.
32. Mascini, M.; Tombelli, S. Biosensors for biomarkers in medical diagnostics. Biomarkers 2008, 13, 637-657.
33. Yoo, E.H.; Lee, S.Y. Glucose biosensors: An overview of use in clinical practice. Sensors 2010, 10, 4558-4576.
34. Weibel, M.K.; Bright, H.J. The glucose oxidase mechanism. Interpretation of the pH dependence. J. Biol. Chem. 1971, 246, 2734-2744.
35. Clark, J.L.C.; Lyons, C. Electrode systems for continuous monitoring in cardiovascular surgery. Ann. N. Y. Acad. Sci. 1962, 102, 29-45.
36. Liu, J.; Wang, J. Improved design for the glucose biosensor. Food Technol. Biotechnol. 2001, 39, 55-58.
37. Turner, A.P.; Chen, B.; Piletsky, S.A. In vitro diagnostics in diabetes: Meeting the challenge. Clin. Chem. 1999, 45, 1596-1601.
38. Zafar, M.N.; Safina, G.; Ludwig, R.; Gorton, L. Characteristics of third-generation glucose biosensors based on Corynascus thermophilus cellobiose dehydrogenase immobilized on commercially available screen-printed electrodes working under physiological conditions. Anal. Biochem. 2012, 425, 36-42.
39. Mohan, R.; Mach, K.E.; Bercovici, M.; Pan, Y.; Dhulipala, L.; Wong, P.K.; Liao, J.C. Clinical validation of integrated nucleic acid and protein detection on an electrochemical biosensor array for urinary tract infection diagnosis. PLoS One 2011, 6, e26846.
40. Liao, J.C.; Mastali, M.; Gau, V.; Suchard, M.A.; Møller, A.K.; Bruckner, D.A.; Babbitt, J.T.; Li, Y.; Gornbein, J.; Landaw, E.M.; et al. Use of Electrochemical DNA biosensors for rapid molecular identification of uropathogens in clinical urine specimens. J. Clin. Microbiol. 2006, 44, 561-570.
41. Shao, H.; Yu, Q.; Bo, X.; Duan, Z. Analysis of oncology research from 2001 to 2010: A scientometric perspective. Oncol. Rep. 2013, 29, 1441-1452.
42. Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.W.; Comber, H.; Forman, D.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49, 1374-1403.
43. Shen, Z. Cancer biomarkers and targeted therapies. Cell Biosci. 2013, 3, 6
44. Uygun, Z.O.; Sezgintürk, M.K. Biosensors for Cancer Biomarkers. In Biosensors-Emerging Materials and Applications; Serr, P.A., Ed.; InTech Open Access Publisher: New York, NY, USA, 2001; pp. 499-544.
45. Rasooly, A.; Jacobson, J. Development of biosensors for cancer clinical testing. Biosens. Bioelectron. 2006, 21, 1851-1858.
46. Glickman, M.H.; Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol. Rev. 2002, 82, 373-428.
47. Orlowski, M.; Wilk, S. Catalytic activities of the 20S proteasome, a multicatalytic proteinase complex. Arch. Biochem. Biophys. 2000, 383, 1-16.
48. Adams, J.; Kauffman, M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Investig. 2004, 22, 304-311.
49. Gorodkiewicz, E.; Ostrowska, H.; Sankiewicz, A. SPR imaging biosensor for the 20S proteasome: Sensor development and application to measurement of proteasomes in human blood plasma. Microchim. Acta 2011, 175, 177-184.
50. Wilson, M.S.; Nie, W. Multiplex measurement of seven tumor markers using an electrochemical protein chip. Anal. Chem. 2006, 78, 6476-6483.
51. Wu, J.; Yan, F.; Tang, J.; Zhai, C.; Ju, H. A disposable multianalyte electrochemical immunosensor array for automated simultaneous determination of tumor markers. Clin. Chem. 2007, 53, 1495-1502.
52. Pimková, K.; Bocková, M.; Hegnerová, K.; Suttnar, J.; Cermák, J.; Homola, J.; Dyr, J.E. Surface plasmon resonance biosensor for the detection of VEGFR-1-A protein marker of myelodysplastic syndromes. Anal. Bioanal. Chem. 2012, 402, 381-387.
53. Salih, H.R.; Nuessler, V.; Denzlinger, C.; Starling, G.C.; Kiener, P.A.; Schmetzer, H.M. Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome. Leuk. Lymphoma 2004, 45, 301-308.
54. Hu, Q.; Dey, A.L.; Yang, Y.; Shen, Y.; Jilani, I.B.; Estey, E.H.; Kantarjian, H.M.; Giles, F.J.; Albitar, M. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer 2004, 100, 1884-1891.
55. Shibuya, M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol. 2006, 39, 469-478.
56. Senger, D.R. Vascular endothelial growth factor: Much more than an angiogenesis factor. Mol. Biol. Cell 2010, 21, 377-379.
57. Belgore, F.M.; Blann, A.D.; Lip, G.Y. Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-I, in fluid samples: Development and application of two new immunoassays. Clin. Sci. 2001, 100, 567-575.
58. Torkaman, A.; Charkari, N.M.; Aghaeipour, M. An approach for leukemia classification based on cooperative game theory. Anal. Cell Pathol. (Amst.) 2011, 34, 235-246.
59. Medley, C.D.; Smith, J.E.; Tang, Z.; Wu, Y.; Bamrungsap, S.; Tan, W. Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells. Anal. Chem. 2008, 80, 1067-1072.
60. Brody, E.N.; Gold, L. Aptamers as therapeutic and diagnostic agents. Rev. Mol. Biotechnol. 2000, 74, 5-13.
61. Shangguan, D.; Li, Y.; Tang, Z.; Cao, Z.C.; Chen, H.W.; Mallikaratchy, P.; Sefah, K.; Yang, C.J.; Tan, W. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. USA 2006, 103, 11838-11843.
62. Grant, C.D.; Schwartzberg, A.M.; Norman, T.J., Jr.; Zhang, J.Z. Ultrafast electronic relaxation and coherent vibrational oscillation of strongly coupled gold nanoparticle aggregates. J. Am. Chem. Soc. 2003, 125, 549-553.
63. Herzenberg, L.A.; Parks, D.; Sahaf, B.; Perez, O.; Roederer, M.; Herzenberg, L.A. The history and future of the fluorescence activated cell sorter and flow cytometry: A view from Stanford. Clin. Chem. 2002, 48, 1819-1827.
64. Chabanas, A.; Rambeaud, J.J.; Huo, H.H.; Seigneurin, D.; Lawrence, J.J. Limits of flow-cytometry histogram analysis methods to assess bladder tumour antigen expression. Anal. Cell Pathol. 1997, 13, 39-47.
65. Fang, X.; Liu, C.; Cheng, X.; Wang, Y.; Yang, Y. A spectral imaging array biosensor and its application in detection of leukemia cell. Sens. Actuators B 2011, 156, 760-764.
66. Piatkowska-Jakubas, B.; Krawczyk-Kuliś, M.; Giebel, S.; Adamczyk-Cioch, M.; Czyz, A.; Lech Marańda, E.; Paluszewska, M.; Palynyczko, G.; Piszcz, J.; Holowiecki, J.; Polish Adult Leukemia Group. Use of L-asparaginase in acute lymphoblastic leukemia: Recommendations of the Polish Adult Leukemia Group. Pol. Arch. Med. Wewn. 2008, 118, 664-669.
67. Panosyan, E.H.; Seibel, N.L.; Martin-Aragon, S.; Gaynon, P.S.; Avramis, I.A.; Sather, H.; Franklin, J.; Nachman, J.; Ettinger, L.J.; La, M. et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J. Pediatr. Hematol. Oncol. 2004, 26, 217-226.
68. Avramis, V.I.; Avramis, E.V.; Hunter, W.; Long, M.C. Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and Surface Plasmon Resonance (SPR-Biacore) assays of IgG Antibodies (Ab) in sera from patients with Acute Lymphoblastic Leukemia (ALL). Anticancer Res. 2009, 29, 299-302.
69. Ferrara, F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol. 2004, 5, 443-450.
70. Hiddemann, W.; Buchner, T. Current status and perspectives of therapies for acute myeloid leukaemia. Semin. Hematol. 2001, 38, 3-9.
71. Daher, G.C.; Harris, B.E.; Diasio, R.B. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol. Ther. 1990, 48, 189-222.
72. Yamauchi, T.; Negoro, E.; Kishi, S.; Takagi, K.; Yoshida, A.; Urasaki, Y.; Iwasaki, H.; Ueda, T. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem. Pharmacol. 2009, 77, 1780-1786.
73. Alloush, H.M.; Anderson, E.; Martin, A.D.; Ruddock, M.W.; Angell, J.E.; Hill, P.J.; Mehta, P.; Smith, M.A.; Smith, J.G.; Salisbury, V.C. A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia. Clin. Chem. 2010, 56, 1862-1870.
74. Cutter, K.L.; Alloush, H.M.; Salisbury, V.C. Stimulation of DNA repair and increased light output in response to UV irradiation in Escherichia coli ex pressing lux genes. Luminescence 2006, 22, 177-181.
75. Anderson, E.; Smith, M.A.; Martin, A.; Ruddock, M.; Lamont, J.; Alloush, H.; Conway, M.; Mehta, P.; Smith, J.G.; Salisbury, V. A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines. Leuk. Res. 2013, (Epub ahead of print).
76. Kurzrock, R.; Gutterman, J.U.; Talpaz, M. The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 1988, 319, 990-998.
77. Sawyers, C. Targeted cancer therapy. Nature 2004, 432, 294-297.
78. Feller, S.M. Crk family adaptors-signalling complex formation and biological roles. Oncogene 2001, 20, 6348-6371.
79. + leukemia. Blood 1994, 84, 1731-1736.
80. White, D.; Saunders, V.; Lyons, A.B.; Branford, S.; Grigg, A.; To, L.B.; Hughes, T. In vitro sensitivity to imatinib induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005, 106, 2520-2526.
81. Mizutani, T.; Kondo, T.; Darmanin, S.; Tsuda, M.; Tanaka, S.; Tobiume, M.; Asaka, M.; Ohba, Y. A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells. Clin. Cancer Res. 2010, 16, 3964-3975.
82. Lu, S., Wang, Y. Fluorescence resonance energy transfer biosensors for cancer detection and evaluation of drug efficacy. Clin. Cancer Res. 2010, 16, 3822-3824.
83. Salahpour, A.; Espinoza, S.; Masri, B.; Lam, V.; Barak, L.S.; Gainetdinov, R.R. BRET biosensors to study GPCR biology, pharmacology, and signal transduction. Front. Endocrinol. (Lausanne) 2012, 3, 105-113.
84. Vainchenker, W.; Constantinescu, S.N. JAK/STAT signaling in hematological malignancies. Oncogene 2012, doi:10.1038/onc.2012.347.
85. Giles, F.J. The vascular endothelial growth factor (VEGF) signaling pathway: A therapeutic target in patients with hematologic malignancies. Oncologist 2001, 6, 32-39.
86. Ge, X.; Wang, X. Role of Wnt canonical pathway in hematological malignancies. J. Hematol. Oncol. 2010, 3, 33-38.
87. Stoppa, G.; Rumiato, E.; Saggioro, D. Ras signaling contributes to survival of human T-cell leukemia/lymphoma virus type 1 (HTLV-1) Tax-positive T-cells. Apoptosis 2012, 17, 219-228.
88. Herman, S.E.; Gordon, A.L.; Hertlein, E.; Ramanunni, A.; Zhang, X.; Jaglowski, S.; Flynn, J.; Jones, J.; Blum, K.A.; Buggy, J.J. et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117, 6287-6296.
89. Pham, L.V.; Ford, R.J. The role of BAFF-R dysregulation in B-lymphoid lineage malignancies. Cell Cycle 2011, 10, 189-190.
90. Lim, K.H.; Yang, Y.; Staudt, L.M. Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol. Rev. 2012, 246, 359-378.
91. Shao, H.; Huang, Q.; Liu, Z.J. Targeting Notch signaling for cancer therapeutic intervention. Adv. Pharmacol. 2012, 65, 191-234.
92. Wöhrle, F.U.; Halbach, S.; Aumann, K.; Schwemmers, S.; Braun, S.; Auberger, P.; Schramek, D.; Penninger, J.M.; Laßmann, S.; Werner, M. et al. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. Leukemia 2012, 27, 118-129.
93. Barrett, D.; Brown, V.I.; Grupp, S.A.; Teachey, D.T. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr. Drugs 2012, 14, 299-316.
94. Pant, V.; Quintás-Cardama, A.; Lozano, G. The p53 pathway in hematopoiesis: Lessons from mouse models, implications for humans. Blood 2012, 120, 5118-5127.
95. Wang, J.C.; Kafeel, M.I.; Avezbakiyev, B.; Chen, C.; Sun, Y.; Rathnasabapathy, C.; Kalavar, M.; He, Z.; Burton, J.; Lichter, S. Histone deacetylase in chronic lymphocytic leukemia. Oncology 2011, 81, 325-329.
96. Ishfaq, M.; Malik, A.; Faiz, M.; Sheikh, I.; Asif, M.; Khan, M.N.; Qureshi, M.S.; Zahid, S.; Manan, A.; Arooj, M. et al. Molecular characterization of flt3 mutations in acute leukemia patients in pakistan. Asian Pac. J. Cancer Prev. 2012, 13, 4581-4585